Harvard Apparatus Regenerative Technology Inc.

What they do

The company is developing regenerative medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma or birth defects. Its lead product candidate, an esophageal implant, was used in the first successful regeneration of the esophagus in a patient with esophageal cancer and is in a 10-patient Phase 1 clinical trial managed by CRO IQVIA; the first site was activated and patient screening began in Q3 2023. Separately, its Hong Kong subsidiary Consumer Health Products sells dietary supplements, which generated the company's reported revenue.

Revenue drivers

• Consumer health / dietary supplements — Revenue comes from the Hong Kong subsidiary Consumer Health Products, which focuses on consumer health products; no approved regenerative medicine product is sold anywhere.
• Regenerative medicine product candidates — The esophageal implant and related regenerative treatments remain in development and have not received regulatory approval for sale anywhere in the world.

Recent performance

Annual revenue rose to $704,000 in 2025 from $430,000 in 2024, after $103,000 in 2023; the company reported no revenue in 2020 or 2021. Quarterly revenue was $123,000 in Q3 2025, $219,000 in Q4 2025, $226,000 in Q1 2026, and $414,000 in Q2 2026. Net losses were $6.9M in 2025, $7.7M in 2024, and $9.0M in 2023, with diluted EPS of -$0.42, -$0.52, and -$0.67, respectively. Operating cash flow was negative every year shown, at -$3.8M in 2025, -$4.9M in 2024, and -$6.9M in 2023. At June 30, 2026, total assets were $1.7M, total liabilities $3.1M, shareholder equity -$1.4M, and cash and equivalents $351,000.

Strategy

The stated priority is advancing the esophageal implant through its 10-patient Phase 1 combination safety and efficacy trial. To address slow enrollment, management says it is increasing the number of trial sites and enhancing patient outreach, after encountering recruitment delays tied to participant comorbid conditions, stringent FDA eligibility criteria, and cross-site logistical difficulties. IQVIA serves as contract research organization for the trial. The company also operates a consumer health products subsidiary that currently supplies reported revenue. It states in its filings it may need to access debt and equity markets to raise additional capital.

Risks

• Clinical trial recruitment delays — The company has encountered delays in patient recruitment driven by participant comorbid conditions, stringent FDA eligibility criteria, and logistical difficulties in enrolling across sites.
• No approved product — The product candidates are in development and have not received regulatory approval for sale anywhere in the world.
• Thin liquidity — At June 30, 2026 the company had $351,000 of cash and equivalents, $3.1M of total liabilities, and negative shareholder equity of $1.4M.
• Capital raising dependence — The company has reported operating cash outflows each year shown and cites its ability to access debt and equity markets and raise additional capital when needed as a key factor.

Outlook

Management's stated focus is completing a trial it describes as measuring both safety and efficacy in the patient population, while working to expand trial sites and outreach to counter recruitment delays. The company continues to depend on the Hong Kong consumer health subsidiary for reported revenue while the regenerative medicine candidates remain pre-approval. It states in the 10-Q that its ability to raise additional capital when needed is a principal area of forward-looking uncertainty.